Skip to Content

Umeclidinium / vilanterol Pregnancy and Breastfeeding Warnings

Umeclidinium / vilanterol is also known as: Anoro Ellipta

Umeclidinium / vilanterol Pregnancy Warnings

There are no adequate and well-controlled trials of this drug or its individual components. Umeclidinium: There was no evidence of teratogenic effects in rats and rabbits at approximately 50 and 200 times the maximum recommended human daily inhaled dose (MRHDID) in adults. Vilanterol: There were no teratogenic effects in rats and rabbits at approximately 13,000 and 70 times the MRHDID in adults. However, fetal skeletal variations were observed in rabbits at approximately 450 times the MRHDID in adults. The skeletal variations included decreased or absent ossification in cervical vertebral centrum and metacarpals. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus. FDA pregnancy category: C Comments: Patients should contact their physicians if they become pregnant while taking this drug.

See references

Umeclidinium / vilanterol Breastfeeding Warnings

Umeclidinium: Administration to lactating rats at approximately 25 times the MRHDID in adults resulted in a quantifiable level of umeclidinium in 2 pups, which may indicate transfer of umeclidinium in milk. Vilanterol: Beta2-agonists have been detected in human milk.

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother. Excreted into human milk: Unknown (umeclidinium and vilanterol) Excreted into animal milk: Yes (umeclidinium), unknown (vilanterol) Comments:The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.

References for breastfeeding information

  1. "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.